Boehringer Ingelheim and Eli Lilly and Company (LLY: Quote) announced that a New Drug Application for the investigational sodium glucose co-transporter-2 inhibitor empagliflozin was recently submitted to the FDA for the treatment of type 2 diabetes mellitus in adults.
Empagliflozin is a member of the SGLT2 inhibitor class of drugs being investigated for the reduction of blood glucose levels in adults with T2D. The emerging SGLT2 inhibitor class removes excess glucose through the urine by blocking glucose re-absorption in the kidney.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org